KRT-232 and TKI Study in Chronic Myeloid Leukemia
Condition:   Chronic Myeloid Leukemia Interventions:   Drug: KRT-232;   Drug: Dasatinib;   Drug: Nilotinib Sponsor:   Kartos Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2021 Category: Research Source Type: clinical trials

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Condition:   CML, Chronic Phase; TKI Interventions:   Drug: Flumatinib Mesylate;   Drug: Nilotinib Pill Sponsor:   The First Affiliated Hospital of Soochow University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2021 Category: Research Source Type: clinical trials

Evaluating Efficacy and Safety of Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) With Defined BCR-ABL1 Kinase Mutations in Imatinib or Dasatinib
Condition:   CML-CP; Mutation;TKI Interventions:   Drug: Flumatinib;   Drug: Nilotinib Sponsor:   Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2020 Category: Research Source Type: clinical trials

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Conditions:   Chronic Myeloid Leukemia;   Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission;   Chronic Myeloid Leukemia in Remission Interventions:   Other: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal;   Drug: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation Sponsor:   Baylor College of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 12, 2020 Category: Research Source Type: clinical trials

Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial)
AbstractObjectivesTo assess the efficacy of several repurposed drugs to prevent hospitalisation or death in patients aged 65 or more with recent symptomatic SARS-CoV-2 infection (COVID-19) and no criteria for hospitalisation.Trial designPhase III, multi-arm (5) and multi-stage (MAMS), randomized, open-label controlled superiority trial.Participants will be randomly allocated 1:1:1:1:1 to the following strategies:Arm 1: Control armArms 2 to 5: Experimental treatment armsPlanned interim analyses will be conducted at regular intervals. Their results will be reviewed by an Independent Data and Safety Monitoring Board. Experime...
Source: Trials - October 13, 2020 Category: Research Source Type: clinical trials

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
Conditions:   Chronic Myeloid Leukemia;   Chronic Myeloid Leukemia in Remission;   BCR-ABL Positive Chronic Myelogenous Leukemia Interventions:   Drug: Imatinib;   Drug: Nilotinib;   Drug: Dasatinib;   Drug: Bosutinib Sponsor:   National Research Center for Hematology, Russia Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 8, 2020 Category: Research Source Type: clinical trials

MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Condition:   Acute Lymphoblastic Leukemia (ALL) Intervention:   Drug: Nilotinib Sponsor:   Novartis Pharmaceuticals Available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 23, 2020 Category: Research Source Type: clinical trials